schliessen

Filtern

 

Bibliotheken

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

Due to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited v... Full description

Journal Title: Urologia internationalis 2015-01, Vol.94 (1), p.1-24
Main Author: Schmitz-Dräger, Bernd J
Other Authors: Droller, Michael , Lokeshwar, Vinata B , Lotan, Yair , Hudson, M''Liss A , van Rhijn, Bas W , Marberger, Michael J , Fradet, Yves , Hemstreet, George P , Malmstrom, Per-Uno , Ogawa, Osamu , Karakiewicz, Pierre I , Shariat, Shahrokh F
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Basel, Switzerland: S. Karger AG
ID: ISSN: 0042-1138
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmed_primary_25501325
title: Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus
format: Article
creator:
  • Schmitz-Dräger, Bernd J
  • Droller, Michael
  • Lokeshwar, Vinata B
  • Lotan, Yair
  • Hudson, M''Liss A
  • van Rhijn, Bas W
  • Marberger, Michael J
  • Fradet, Yves
  • Hemstreet, George P
  • Malmstrom, Per-Uno
  • Ogawa, Osamu
  • Karakiewicz, Pierre I
  • Shariat, Shahrokh F
subjects:
  • Biomarkers, Tumor - genetics
  • Biomarkers, Tumor - urine
  • Bladder cancer
  • Cancer
  • Clinical Medicine
  • Consensus
  • Diagnosis
  • Early Detection of Cancer - methods
  • Humans
  • Klinisk medicin
  • Medical and Health Sciences
  • Medicin och hälsovetenskap
  • Methods
  • Molecular Diagnostic Techniques
  • Molecular markers
  • Practice Guidelines as Topic
  • Predictive Value of Tests
  • Prognosis
  • Reproducibility of Results
  • Review
  • Risk Assessment
  • Risk Factors
  • Societies, Medical
  • Surveillance
  • Urinalysis
  • Urinary Bladder Neoplasms - diagnosis
  • Urinary Bladder Neoplasms - epidemiology
  • Urinary Bladder Neoplasms - genetics
  • Urinary Bladder Neoplasms - urine
  • Urine
  • Urologi och njurmedicin
  • Urology and Nephrology
  • World Health Organization
ispartof: Urologia internationalis, 2015-01, Vol.94 (1), p.1-24
description: Due to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0042-1138
fulltext: fulltext
issn:
  • 0042-1138
  • 1423-0399
  • 1423-0399
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6234434
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmed_primary_25501325
sourceformatXML
sourcesystemPC
galeidA637473103
sourcerecordidA637473103
originalsourceidFETCH-LOGICAL-1503t-588083bb4839001647d988c12af59c92a593a1ca0d12986903bed8ecf18896b83
addsrcrecordideNqNkl1rFDEYhYModq1e-AckIBSVnW4ymY_Eu3W22oXWXrSrlyGTeWeNnU3WZEbpvzfD1AWlF5LAC-E5JyecIPSSklNKc7EghLBCsLx8hGY0S1lCmBCP0YyQLE0oZfwIPQvhOyERFuVTdJTmOaEszWfIXLoO9NApjy-VvwUfcOs8_tCppgGPK2V1HNfaA1hjt3N8pnx3h1dGba0LJsyxsg2-HvxPMF030u_xzTfAX8-vFutqs8KVswFsGMJz9KRVXYAX9_MYbT6e3VTnycXVp3W1vEhoTlif5JwTzuo640zEwEVWNoJzTVPV5kKLVOWCKaoVaWgqeCEIq6HhoFvKuShqzo7RfPINv2A_1HLvzU75O-mUkSvzZSmd38phkGlWFnTE30z43rsfA4Re7kzQML4F3BAkLXIWbyKijOjrCd2qDqSxreu90iMulwUrs5JRwiJ1-gAVVwM7o52F1sTzvwRvJ4H2LgQP7SEyJXLsVx76jeyr-7RDvYPmQP4pNAKLf8y06VVvnI0pTPeg5cmkuFV-C_5guVl_TuOHISKLNcQdwXf_Bcp907LfGjXDog
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1653129097
display
typearticle
titleMolecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus
sourceAlma/SFX Local Collection
creatorSchmitz-Dräger, Bernd J ; Droller, Michael ; Lokeshwar, Vinata B ; Lotan, Yair ; Hudson, M''Liss A ; van Rhijn, Bas W ; Marberger, Michael J ; Fradet, Yves ; Hemstreet, George P ; Malmstrom, Per-Uno ; Ogawa, Osamu ; Karakiewicz, Pierre I ; Shariat, Shahrokh F
creatorcontribSchmitz-Dräger, Bernd J ; Droller, Michael ; Lokeshwar, Vinata B ; Lotan, Yair ; Hudson, M''Liss A ; van Rhijn, Bas W ; Marberger, Michael J ; Fradet, Yves ; Hemstreet, George P ; Malmstrom, Per-Uno ; Ogawa, Osamu ; Karakiewicz, Pierre I ; Shariat, Shahrokh F
descriptionDue to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.
identifier
0ISSN: 0042-1138
1ISSN: 1423-0399
2EISSN: 1423-0399
3DOI: 10.1159/000369357
4PMID: 25501325
languageeng
publisherBasel, Switzerland: S. Karger AG
subjectBiomarkers, Tumor - genetics ; Biomarkers, Tumor - urine ; Bladder cancer ; Cancer ; Clinical Medicine ; Consensus ; Diagnosis ; Early Detection of Cancer - methods ; Humans ; Klinisk medicin ; Medical and Health Sciences ; Medicin och hälsovetenskap ; Methods ; Molecular Diagnostic Techniques ; Molecular markers ; Practice Guidelines as Topic ; Predictive Value of Tests ; Prognosis ; Reproducibility of Results ; Review ; Risk Assessment ; Risk Factors ; Societies, Medical ; Surveillance ; Urinalysis ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - epidemiology ; Urinary Bladder Neoplasms - genetics ; Urinary Bladder Neoplasms - urine ; Urine ; Urologi och njurmedicin ; Urology and Nephrology ; World Health Organization
ispartofUrologia internationalis, 2015-01, Vol.94 (1), p.1-24
rights
02014 S. Karger AG, Basel
12014 S. Karger AG, Basel.
2COPYRIGHT 2015 S. Karger AG
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1503t-588083bb4839001647d988c12af59c92a593a1ca0d12986903bed8ecf18896b83
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25501325$$D View this record in MEDLINE/PubMed
1$$Uhttp://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-247618$$DView record from Swedish Publication Index
search
creatorcontrib
0Schmitz-Dräger, Bernd J
1Droller, Michael
2Lokeshwar, Vinata B
3Lotan, Yair
4Hudson, M''Liss A
5van Rhijn, Bas W
6Marberger, Michael J
7Fradet, Yves
8Hemstreet, George P
9Malmstrom, Per-Uno
10Ogawa, Osamu
11Karakiewicz, Pierre I
12Shariat, Shahrokh F
title
0Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus
1Urologia internationalis
addtitleUrol Int
descriptionDue to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.
subject
0Biomarkers, Tumor - genetics
1Biomarkers, Tumor - urine
2Bladder cancer
3Cancer
4Clinical Medicine
5Consensus
6Diagnosis
7Early Detection of Cancer - methods
8Humans
9Klinisk medicin
10Medical and Health Sciences
11Medicin och hälsovetenskap
12Methods
13Molecular Diagnostic Techniques
14Molecular markers
15Practice Guidelines as Topic
16Predictive Value of Tests
17Prognosis
18Reproducibility of Results
19Review
20Risk Assessment
21Risk Factors
22Societies, Medical
23Surveillance
24Urinalysis
25Urinary Bladder Neoplasms - diagnosis
26Urinary Bladder Neoplasms - epidemiology
27Urinary Bladder Neoplasms - genetics
28Urinary Bladder Neoplasms - urine
29Urine
30Urologi och njurmedicin
31Urology and Nephrology
32World Health Organization
issn
00042-1138
11423-0399
21423-0399
fulltexttrue
rsrctypearticle
creationdate2015
recordtypearticle
recordideNqNkl1rFDEYhYModq1e-AckIBSVnW4ymY_Eu3W22oXWXrSrlyGTeWeNnU3WZEbpvzfD1AWlF5LAC-E5JyecIPSSklNKc7EghLBCsLx8hGY0S1lCmBCP0YyQLE0oZfwIPQvhOyERFuVTdJTmOaEszWfIXLoO9NApjy-VvwUfcOs8_tCppgGPK2V1HNfaA1hjt3N8pnx3h1dGba0LJsyxsg2-HvxPMF030u_xzTfAX8-vFutqs8KVswFsGMJz9KRVXYAX9_MYbT6e3VTnycXVp3W1vEhoTlif5JwTzuo640zEwEVWNoJzTVPV5kKLVOWCKaoVaWgqeCEIq6HhoFvKuShqzo7RfPINv2A_1HLvzU75O-mUkSvzZSmd38phkGlWFnTE30z43rsfA4Re7kzQML4F3BAkLXIWbyKijOjrCd2qDqSxreu90iMulwUrs5JRwiJ1-gAVVwM7o52F1sTzvwRvJ4H2LgQP7SEyJXLsVx76jeyr-7RDvYPmQP4pNAKLf8y06VVvnI0pTPeg5cmkuFV-C_5guVl_TuOHISKLNcQdwXf_Bcp907LfGjXDog
startdate201501
enddate201501
creator
0Schmitz-Dräger, Bernd J
1Droller, Michael
2Lokeshwar, Vinata B
3Lotan, Yair
4Hudson, M''Liss A
5van Rhijn, Bas W
6Marberger, Michael J
7Fradet, Yves
8Hemstreet, George P
9Malmstrom, Per-Uno
10Ogawa, Osamu
11Karakiewicz, Pierre I
12Shariat, Shahrokh F
generalS. Karger AG
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
87X8
9ADTPV
10AOWAS
sort
creationdate201501
titleMolecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus
authorSchmitz-Dräger, Bernd J ; Droller, Michael ; Lokeshwar, Vinata B ; Lotan, Yair ; Hudson, M''Liss A ; van Rhijn, Bas W ; Marberger, Michael J ; Fradet, Yves ; Hemstreet, George P ; Malmstrom, Per-Uno ; Ogawa, Osamu ; Karakiewicz, Pierre I ; Shariat, Shahrokh F
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1503t-588083bb4839001647d988c12af59c92a593a1ca0d12986903bed8ecf18896b83
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Biomarkers, Tumor - genetics
1Biomarkers, Tumor - urine
2Bladder cancer
3Cancer
4Clinical Medicine
5Consensus
6Diagnosis
7Early Detection of Cancer - methods
8Humans
9Klinisk medicin
10Medical and Health Sciences
11Medicin och hälsovetenskap
12Methods
13Molecular Diagnostic Techniques
14Molecular markers
15Practice Guidelines as Topic
16Predictive Value of Tests
17Prognosis
18Reproducibility of Results
19Review
20Risk Assessment
21Risk Factors
22Societies, Medical
23Surveillance
24Urinalysis
25Urinary Bladder Neoplasms - diagnosis
26Urinary Bladder Neoplasms - epidemiology
27Urinary Bladder Neoplasms - genetics
28Urinary Bladder Neoplasms - urine
29Urine
30Urologi och njurmedicin
31Urology and Nephrology
32World Health Organization
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Schmitz-Dräger, Bernd J
1Droller, Michael
2Lokeshwar, Vinata B
3Lotan, Yair
4Hudson, M''Liss A
5van Rhijn, Bas W
6Marberger, Michael J
7Fradet, Yves
8Hemstreet, George P
9Malmstrom, Per-Uno
10Ogawa, Osamu
11Karakiewicz, Pierre I
12Shariat, Shahrokh F
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7MEDLINE - Academic
8SwePub
9SwePub Articles
jtitleUrologia internationalis
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Schmitz-Dräger, Bernd J
1Droller, Michael
2Lokeshwar, Vinata B
3Lotan, Yair
4Hudson, M''Liss A
5van Rhijn, Bas W
6Marberger, Michael J
7Fradet, Yves
8Hemstreet, George P
9Malmstrom, Per-Uno
10Ogawa, Osamu
11Karakiewicz, Pierre I
12Shariat, Shahrokh F
formatjournal
genrearticle
ristypeJOUR
atitleMolecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus
jtitleUrologia internationalis
addtitleUrol Int
date2015-01
risdate2015
volume94
issue1
spage1
epage24
pages1-24
issn
00042-1138
11423-0399
eissn1423-0399
abstractDue to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.
copBasel, Switzerland
pubS. Karger AG
pmid25501325
doi10.1159/000369357
tpages24
oafree_for_read